AVEVA 1H07 revenue, pretax profit maintains hectic pace of growth thanks to R&D spend, bouyant markets

Star Silicon Fen performer AVEVA Group plc (AVV.L), one of the world's leading providers of engineering data and design IT systems, reported strong growth in revenues and profits on the back of buoyant marine, oil, gas and power markets in the six months ended 30 September.

Chairman Nick Prest (pictured) said: "AVEVA has built an excellent reputation amongst the world's leading engineering companies for innovative products and first class support.

“Our significant investment in R&D and resulting launch of new products into strongly growing markets position the Company for further expansion. In addition, the maturing of the new AVEVA NET products will provide an additional platform for sales into the Owner / Operator market."

However, the Group’s share price slid 48p to 1100p in early trading, after a period of steady growth since September lows of around 800p. It is now valued at around £740m.

Mr Prest said operating margins continued to improve in 1H and were 28% in the first half, up from 27% in 1H06.

“Margins over recent periods have increased and are being driven by growth in sales, and in particular Initial fee income. Offsetting this, however, has been the Company's continued investment across the business, in particular in R & D, which has helped support the growth rates seen over recent periods,” he said.

The Group's strong first half trading benefited from increased contribution from all regions.

Investment in R & D was 18% of turnover at £10.2m, compared to £7.2m in 1H2006.

Mr Prest said the investment in R & D and launch of new products into strongly growing markets positioned AVEVA for further expansion. In addition, the maturing of the new AVEVA NET products will provide an additional platform for sales into the Owner / Operator market.

12th November 2007

Previous articles
Xaar bounces back to revenue growth in 1H07, buoyed by Americas, Asia, and especially China
Phytopharm, Unilever stop working together on Hoodia; Camrivox partners with snow to add VoIP to Microsoft Outlook
Briefs: OpenCloud raises $10m in 2nd round funding; Antitope signs research deal with Fusion Antibodies
Acambis’ new CEO to get feet under the table in time for financial results: FDA to review its smallpox vaccine
£30 million venture capital pumped into Cambridge Cluster high-tech firms in past 3 months
Acambis gets £10m yellow fever vaccine settlement; results ‘encouraging’ from West Nile virus vaccine trial
Briefs: Aveva expects strong results in 1H08; New CEO for Screen Technology; PACSMail in football injuries trial
ANT revenues grow, losses narrow as the way media content is viewed morphs
CSR reports strong 4Q2009, “market traction” with renewed portfolio
Autonomy's 'extraordinary' '06 sees revenues up 161%, operating profits soar 275%
Subscribe

 

Managed Hosting by NTT Managed Hosting
SEO London by IdeaTaxi.com
Corporate profiles

 • CeNeS Pharmaceuticals


Simon Kerr
Commercial Director


CeNeS is exploiting a low risk, accelerated approach to a number of the unmet medical needs of the $53 billion plus central nervous system drug market. Its mission is to discover and develop treatments for disorders related to the Central Nervous System, particularly in the areas of pain, anaesthesia

[CeNeS Pharmaceuticals's profile]


Top20 Index




Currently: 161